Quick Answer
Vanda Pharmaceuticals Inc. reported R&D Expense of $109.27 million for fiscal year 2025.
Vanda Pharmaceuticals Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $109.27M | +46.8% |
| 2024 | $74.43M | -3.1% |
| 2023 | $76.82M | -10.4% |
| 2022 | $85.77M | +13.8% |
| 2021 | $75.36M | +35.6% |
| 2020 | $55.58M | +14.2% |
| 2019 | $48.65M | +11.6% |
| 2018 | $43.59M | +13.1% |
| 2017 | $38.55M | +32.2% |
| 2016 | $29.16M | +0.0% |
| 2015 | $29.14M | +51.6% |
| 2014 | $19.23M | -32.5% |
| 2013 | $28.50M | -37.7% |
| 2012 | $45.76M | +57.8% |
| 2011 | $29.00M | +135.0% |
| 2010 | $12.34M | -11.1% |
| 2009 | $13.87M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.56M | +34.5% | +2.6% |
| June 30, 2025 | $21.99M | +32.0% | -38.4% |
| March 31, 2025 | $35.71M | +68.8% | +112.9% |
| September 30, 2024 | $16.78M | +1.1% | +0.7% |
| June 30, 2024 | $16.66M | +0.1% | -21.2% |
| March 31, 2024 | $21.15M | +10.0% | +27.4% |
| September 30, 2023 | $16.60M | -33.2% | -0.3% |
| June 30, 2023 | $16.65M | -22.5% | -13.5% |
- Vanda Pharmaceuticals Inc. showed an increase of +46.8% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, Vanda Pharmaceuticals Inc.’s r&d expense has grown by 687.6% (from $13.87 million to $109.27 million).
- The most recent figure is from Vanda Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: